- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07707232
Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports (PSMA-LLM-cTNM)
Large Language Model-Assisted Imaging cTNM Staging Annotation and Uncertainty Recognition for Prostate Cancer Based on Chinese PSMA PET/CT Reports
This observational study will develop and validate a large language model-assisted workflow for imaging cTNM staging annotation and uncertainty recognition in prostate cancer using Chinese PSMA PET/CT report texts generated during routine clinical care. The study will use de-identified report texts and necessary baseline clinical information only. No additional imaging examination, blood test, treatment, or follow-up visit will be assigned for this study.
The main objective is to evaluate whether a locally or institutionally controlled large language model can identify report-derived imaging cT, cN, and cM categories, extract supporting evidence from the original report, and recognize uncertainty expressions. Model performance will be assessed using an internal independent validation set, external validation reports from two collaborating hospitals, and a prospective validation set of 100 consecutive routine PSMA PET/CT reports. A human-AI comparison will also be performed using physicians from urology and imaging-related specialties with different seniority levels.
연구 개요
상세 설명
This is a multicenter observational diagnostic accuracy validation study based on Chinese PSMA PET/CT report texts from patients with prostate cancer or suspected prostate cancer. The study is not designed to evaluate a drug, device, surgical procedure, or imaging intervention. PSMA PET/CT examinations will be performed as part of routine clinical care, and the study will only analyze de-identified report texts and necessary baseline information after the reports have been finalized.
The study consists of retrospective and prospective components. Retrospectively, approximately 4,000 PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University will be systematically annotated to construct a research database. An internal independent validation set of 300 reports, not used for model development or prompt optimization, will be used to evaluate the performance of the large language model. The reference standard for this 300-report validation set will be established by two experienced urologists through joint annotation, with adjudication by a nuclear medicine expert when needed. External validation will be performed using 110 de-identified reports from the First Affiliated Hospital of Ningbo University and 102 de-identified reports from Liuzhou People's Hospital. In addition, after ethics approval, 100 consecutive routine PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University will be prospectively included to evaluate the accuracy and operational stability of the frozen model and prompt versions.
The large language model workflow will be deployed locally or in an institutionally controlled environment. The model will be instructed to generate structured JSON outputs, including cT_report, cN_report, cM_report, cT_uncertain, cN_uncertain, cM_uncertain, evidence_T, evidence_N, and evidence_M. The target task is report-derived imaging cTNM staging annotation, not pathological TNM staging or overall AJCC stage grouping. The model output will be used only for research evaluation and methodological analysis and will not be used for clinical diagnosis, treatment decision-making, or patient notification.
A human-AI comparison will be conducted on the 300-report internal validation set. Eight human evaluators from urology and imaging-related specialties, including trainees, residents, attending physicians, and associate chief physicians, will independently annotate the reports before and after learning the annotation manual. Annotation time will be recorded for each round. The performance of human evaluators and the large language model will be compared against the expert consensus reference standard.
The main outcome will be the accuracy of the large language model in identifying cT, cN, and cM categories from Chinese PSMA PET/CT reports. Secondary outcomes will include precision, recall, F1-score, macro-F1, micro-F1, complete cTNM triplet matching rate, uncertainty recognition performance, evidence extraction quality, human-AI comparison results, annotation time, external validation performance, prospective validation performance, and error type distribution. Error analysis will focus on local tumor extent, regional versus non-regional lymph node boundaries, bone and visceral metastasis recognition, equivocal wording, treatment-related context, benign or inflammatory alternatives, and lesions not attributable to prostate cancer.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Qi Lin
- 전화번호: +86 15205771010
- 이메일: devillynch@126.com
연구 연락처 백업
- 이름: Yikai Chen
- 전화번호: +86 13857730804
- 이메일: chenyikai@wzhospital.cn
연구 장소
-
-
Zhejiang
-
Wenzhou, Zhejiang, 중국
- The First Affiliated Hospital of Wenzhou Medical University
-
연락하다:
- Qi Lin
- 전화번호: +86 15205771010
- 이메일: devillynch@126.com
-
연락하다:
- Yikai Chen
- 전화번호: +86 13857730804
- 이메일: chenyikai@wzhospital.cn
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Male patients aged 18 years or older.
- Patients with clinically diagnosed, pathologically diagnosed, or clinically suspected prostate cancer.
- Patients who underwent PSMA PET/CT for initial staging, recurrence assessment, treatment response evaluation, metastatic assessment, or other clinical purposes during routine care.
- Complete or basically complete Chinese PSMA PET/CT report text is available, including imaging findings and/or diagnostic impression.
- The report text contains information that can be used to evaluate at least one target field, such as local prostate lesion, regional lymph nodes, non-regional lymph nodes, bone metastasis, visceral metastasis, or uncertainty expressions.
- The research data can be de-identified and replaced by a study identification number before analysis.
Exclusion Criteria:
- PSMA PET/CT reports unrelated to prostate cancer, or reports clearly irrelevant to the research task.
- Reports with severely missing, unreadable, or unavailable main text, imaging findings, or diagnostic impression.
- Reports that cannot be adequately de-identified or contain residual direct personal identifiers that cannot be safely removed.
- Duplicate records, repeated exports of the same examination, or records for which the unique report version cannot be confirmed.
- Reports judged by the research team to be of insufficient quality for manual annotation, model evaluation, or statistical analysis.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
PSMA PET/CT Report Text Validation Cohort
Patients with prostate cancer or suspected prostate cancer who underwent PSMA PET/CT as part of routine clinical care.
De-identified Chinese PSMA PET/CT report texts and necessary baseline information will be used for manual annotation, large language model-assisted imaging cTNM staging annotation, uncertainty recognition, internal validation, external validation, prospective validation, and human-AI comparison.
No additional examination, treatment, or follow-up will be assigned for this study.
|
A locally or institutionally controlled large language model workflow will analyze de-identified Chinese PSMA PET/CT report texts and generate structured outputs for report-derived imaging cTNM staging annotation, uncertainty recognition, and supporting evidence extraction.
This workflow is used only for research evaluation and methodological analysis.
It will not assign any examination, treatment, medication, procedure, or follow-up to participants, and it will not guide clinical diagnosis or treatment decisions.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Accuracy of LLM-Assisted Imaging cTNM Staging Annotation
기간: After freezing the model and prompt versions, through completion of internal, external, and prospective validation, up to 18 months
|
The primary outcome is the accuracy of the large language model in identifying report-derived imaging cT, cN, and cM categories from de-identified Chinese PSMA PET/CT report texts.
The LLM-generated cT_report, cN_report, and cM_report will be compared with the expert consensus reference standard.
Accuracy, precision, recall, F1-score, macro-F1, micro-F1, complete cTNM triplet matching rate, and confusion matrices will be calculated in the internal 300-report validation set, external validation sets, and prospective 100-report validation set.
|
After freezing the model and prompt versions, through completion of internal, external, and prospective validation, up to 18 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Component-Level Accuracy of LLM-Based Uncertainty Recognition
기간: After freezing the model and prompt versions, through completion of all validation analyses, up to 18 months.
|
This outcome measures the component-level accuracy of the large language model in recognizing uncertainty labels for report-derived imaging cTNM staging. The LLM-generated cT_uncertain, cN_uncertain, and cM_uncertain labels will be compared with the expert consensus reference standard. Accuracy will be calculated as the number of correctly classified uncertainty labels divided by the total number of component-level uncertainty labels across all reports. The three uncertainty components will be aggregated into one percentage value. 中文对应 |
After freezing the model and prompt versions, through completion of all validation analyses, up to 18 months.
|
|
Complete cTNM Triplet Matching Rate for Human Evaluators and the LLM
기간: During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
|
This outcome measures the proportion of reports for which the complete report-derived imaging cTNM triplet assigned by human evaluators and by the large language model exactly matches the expert consensus reference standard.
A report will be counted as correct only when all three components, cT_report, cN_report, and cM_report, are correct.
The result will be reported as the percentage of reports with complete cTNM triplet agreement.
Results will be summarized separately for pre-training human annotation, post-training human annotation, and LLM batch inference.
|
During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
|
|
Annotation Time per Report for Human Evaluators and the LLM
기간: During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
|
This outcome measures the mean time required to complete report-derived imaging cTNM annotation per report.
For human evaluators, annotation time will be recorded during the annotation rounds and divided by the number of annotated reports.
For the LLM workflow, batch inference time will be divided by the number of processed reports.
Results will be reported separately for pre-training human annotation, post-training human annotation, and LLM batch inference.
|
During pre-training and post-training human annotation rounds and LLM batch inference, up to 18 months.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- KY2026-278
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전립선암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Weill Medical College of Cornell UniversityMillennium Pharmaceuticals, Inc.완전한신경내분비성 전립선암 | 소세포 전립선암 | Prostate Adenocarcinoma Plus > 신경내분비 표지자에 대한 50% 면역조직화학적 염색미국
-
SB Istanbul Education and Research Hospital아직 모집하지 않음Thryoid cancer | parathyrıoid 선종
-
Jonsson Comprehensive Cancer CenterNovartis Pharmaceuticals모병전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | 2기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Society for Endocrinology초대로 등록
-
Jonsson Comprehensive Cancer Center모병거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국